Business Description
INmune Bio Inc
NAICS : 325412
SIC : 2834
ISIN : US45782T1051
Description
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products includeINKmune, INBO3, XPro1595, LIVNate, and others.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 11.52 | |||||
| Equity-to-Asset | 0.73 | |||||
| Debt-to-Equity | 0.08 | |||||
| Debt-to-EBITDA | -0.07 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | -1.21 | |||||
| Beneish M-Score | -3.13 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 108 | |||||
| 3-Year EBITDA Growth Rate | -17.5 | |||||
| 3-Year EPS without NRI Growth Rate | -18.2 | |||||
| 3-Year FCF Growth Rate | 3.7 | |||||
| 3-Year Book Growth Rate | -9.6 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | -51.19 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 36.75 | |||||
| 9-Day RSI | 41.7 | |||||
| 14-Day RSI | 43.3 | |||||
| 3-1 Month Momentum % | -11.42 | |||||
| 6-1 Month Momentum % | -35.31 | |||||
| 12-1 Month Momentum % | -45.16 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.59 | |||||
| Quick Ratio | 2.59 | |||||
| Cash Ratio | 2.43 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -10 | |||||
| Shareholder Yield % | 6.93 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -98921.43 | |||||
| Net Margin % | -98266.67 | |||||
| FCF Margin % | -61307.14 | |||||
| ROE % | -109.97 | |||||
| ROA % | -75.93 | |||||
| ROIC % | -168.78 | |||||
| 3-Year ROIIC % | -167.57 | |||||
| ROC (Joel Greenblatt) % | -10680.46 | |||||
| ROCE % | -107.85 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 1735.85 | |||||
| PB Ratio | 2.8 | |||||
| Price-to-Tangible-Book | 4.87 | |||||
| EV-to-EBIT | -2.06 | |||||
| EV-to-EBITDA | -2.06 | |||||
| EV-to-Revenue | 2042.05 | |||||
| EV-to-Forward-Revenue | 7480.59 | |||||
| EV-to-FCF | -3.33 | |||||
| Price-to-GF-Value | 2.21 | |||||
| Price-to-Net-Current-Asset-Value | 4.87 | |||||
| Price-to-Net-Cash | 5.43 | |||||
| Earnings Yield (Greenblatt) % | -48.54 | |||||
| FCF Yield % | -23.85 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:INMB
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
INmune Bio Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.042 | ||
| EPS (TTM) ($) | -2.18 | ||
| Beta | 0.75 | ||
| 3-Year Sharpe Ratio | -0.35 | ||
| 3-Year Sortino Ratio | -0.5 | ||
| Volatility % | 44.05 | ||
| 14-Day RSI | 43.3 | ||
| 14-Day ATR ($) | 0.351227 | ||
| 20-Day SMA ($) | 5.00275 | ||
| 12-1 Month Momentum % | -45.16 | ||
| 52-Week Range ($) | 4.45 - 14.74 | ||
| Shares Outstanding (Mil) | 22.17 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
INmune Bio Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
INmune Bio Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
INmune Bio Inc Frequently Asked Questions
What is INmune Bio Inc(INMB)'s stock price today?
The current price of INMB is $4.76. The 52 week high of INMB is $14.74 and 52 week low is $4.45.
When is next earnings date of INmune Bio Inc(INMB)?
The next earnings date of INmune Bio Inc(INMB) is 2025-03-28 Est..
Does INmune Bio Inc(INMB) pay dividends? If so, how much?
INmune Bio Inc(INMB) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers